KURA – Kura Oncology, Inc.
Kura Oncology, Inc.KURA
$5.90Name : Kura Oncology, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $476,587,840.00
EPSttm : -2.02
Kura Oncology, Inc.
$5.90
2.61%$0.15Float Short %
11.71
Margin Of Safety %
-15
Put/Call OI Ratio
0.18
EPS Next Q Diff
-0.38
EPS Last/This Y
-0.17
EPS This/Next Y
-0.21
Price
5.9
Target Price
28
Analyst Recom
1.33
Performance Q
-17.83
Relative Volume
0.61
Beta
0.55
Ticker: KURA
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-19 | KURA | 7.27 | 0.30 | 999.99 | 5699 |
| 2025-03-20 | KURA | 7.86 | 0.30 | 0.00 | 5702 |
| 2025-03-21 | KURA | 7.8 | 0.30 | 0.25 | 5719 |
| 2025-03-24 | KURA | 7.65 | 0.15 | 2.29 | 4731 |
| 2025-03-25 | KURA | 7.11 | 0.15 | 1.76 | 4754 |
| 2025-03-26 | KURA | 7.13 | 0.19 | 0.00 | 5067 |
| 2025-03-27 | KURA | 7.13 | 0.19 | 0.00 | 5101 |
| 2025-03-28 | KURA | 7.04 | 0.19 | 1.47 | 5253 |
| 2025-03-31 | KURA | 6.59 | 0.22 | 0.03 | 5450 |
| 2025-04-01 | KURA | 6.38 | 0.22 | 0.00 | 5527 |
| 2025-04-02 | KURA | 6.53 | 0.22 | 0.00 | 5541 |
| 2025-04-03 | KURA | 6.18 | 0.22 | 0.16 | 5567 |
| 2025-04-04 | KURA | 5.89 | 0.22 | 0.00 | 5568 |
| 2025-04-07 | KURA | 5.76 | 0.22 | 1.67 | 5564 |
| 2025-04-08 | KURA | 5.64 | 0.22 | 0.50 | 5558 |
| 2025-04-09 | KURA | 5.96 | 0.22 | 0.50 | 5558 |
| 2025-04-10 | KURA | 5.64 | 0.22 | 0.92 | 5558 |
| 2025-04-11 | KURA | 5.78 | 0.22 | 0.92 | 5558 |
| 2025-04-14 | KURA | 5.84 | 0.19 | 0.00 | 5427 |
| 2025-04-15 | KURA | 6.02 | 0.19 | 0.00 | 5443 |
| 2025-04-16 | KURA | 5.74 | 0.18 | 5.00 | 5563 |
| 2025-04-17 | KURA | 5.89 | 0.18 | 5.00 | 5563 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-19 | KURA | 7.27 | -12.9 | - | -2.19 |
| 2025-03-20 | KURA | 7.85 | -12.9 | - | -2.12 |
| 2025-03-21 | KURA | 7.83 | -12.9 | - | -2.12 |
| 2025-03-24 | KURA | 7.65 | -8.9 | - | -2.12 |
| 2025-03-25 | KURA | 7.12 | -8.9 | - | -2.12 |
| 2025-03-26 | KURA | 7.14 | -8.9 | - | -2.12 |
| 2025-03-27 | KURA | 7.12 | -8.9 | - | -2.12 |
| 2025-03-28 | KURA | 7.05 | -8.9 | - | -2.12 |
| 2025-03-31 | KURA | 6.60 | -8.9 | - | -2.12 |
| 2025-04-01 | KURA | 6.38 | -8.9 | - | -2.12 |
| 2025-04-02 | KURA | 6.52 | -8.9 | - | -2.12 |
| 2025-04-03 | KURA | 6.17 | -8.9 | - | -2.12 |
| 2025-04-04 | KURA | 5.89 | -8.9 | - | -2.12 |
| 2025-04-07 | KURA | 5.77 | -8.9 | - | -2.12 |
| 2025-04-08 | KURA | 5.62 | -8.9 | - | -2.12 |
| 2025-04-09 | KURA | 5.96 | -8.9 | - | -2.12 |
| 2025-04-10 | KURA | 5.65 | -8.9 | - | -2.12 |
| 2025-04-11 | KURA | 5.76 | -8.9 | - | -2.15 |
| 2025-04-14 | KURA | 5.85 | -6.6 | - | -2.19 |
| 2025-04-15 | KURA | 6.03 | -1.7 | - | -2.19 |
| 2025-04-16 | KURA | 5.74 | -1.7 | - | -2.19 |
| 2025-04-17 | KURA | 5.90 | -1.7 | - | -2.19 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-19 | KURA | -0.41 | 0.45 | 12.26 |
| 2025-03-20 | KURA | -0.41 | 0.45 | 12.26 |
| 2025-03-21 | KURA | -0.41 | 0.45 | 12.26 |
| 2025-03-24 | KURA | -0.81 | 0.44 | 12.26 |
| 2025-03-25 | KURA | -0.81 | 0.44 | 12.26 |
| 2025-03-26 | KURA | -0.81 | 0.44 | 12.01 |
| 2025-03-27 | KURA | -0.81 | 0.44 | 12.01 |
| 2025-03-28 | KURA | -0.81 | 0.44 | 12.01 |
| 2025-03-31 | KURA | -0.81 | 0.49 | 12.01 |
| 2025-04-01 | KURA | -0.81 | 0.49 | 12.01 |
| 2025-04-02 | KURA | -0.81 | 0.49 | 12.01 |
| 2025-04-03 | KURA | -0.81 | 0.49 | 12.01 |
| 2025-04-04 | KURA | -0.81 | 0.49 | 12.01 |
| 2025-04-07 | KURA | -0.81 | 0.49 | 12.01 |
| 2025-04-08 | KURA | -0.81 | 0.49 | 12.01 |
| 2025-04-09 | KURA | -0.81 | 0.49 | 12.01 |
| 2025-04-10 | KURA | -0.81 | 0.49 | 11.71 |
| 2025-04-11 | KURA | -0.81 | 0.49 | 11.71 |
| 2025-04-14 | KURA | -0.81 | 0.63 | 11.71 |
| 2025-04-15 | KURA | -0.81 | 0.63 | 11.71 |
| 2025-04-16 | KURA | -0.81 | 0.63 | 11.71 |
| 2025-04-17 | KURA | -0.81 | 0.63 | 11.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.22
Avg. EPS Est. Current Quarter
-0.64
Avg. EPS Est. Next Quarter
-0.6
Insider Transactions
-0.81
Institutional Transactions
0.63
Beta
0.55
Average Sales Estimate Current Quarter
39
Average Sales Estimate Next Quarter
22
Fair Value
5.01
Quality Score
29
Growth Score
26
Sentiment Score
11
Actual DrawDown %
86.3
Max Drawdown 5-Year %
-86.5
Target Price
28
P/E
Forward P/E
PEG
P/S
8.85
P/B
1.12
P/Free Cash Flow
3.56
EPS
-2.02
Average EPS Est. Cur. Y
-2.19
EPS Next Y. (Est.)
-2.41
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-322.89
Relative Volume
0.61
Return on Equity vs Sector %
-61.6
Return on Equity vs Industry %
-48.6
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
EBIT Estimation
Kura Oncology, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 192
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
stock quote shares KURA – Kura Oncology, Inc. Stock Price stock today
news today KURA – Kura Oncology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KURA – Kura Oncology, Inc. yahoo finance google finance
stock history KURA – Kura Oncology, Inc. invest stock market
stock prices KURA premarket after hours
ticker KURA fair value insiders trading